Raphics, detailed information on antiretroviral treatment, laboratory parameters and clinical eventsRaphics, detailed information on antiretroviral

Raphics, detailed information on antiretroviral treatment, laboratory parameters and clinical events
Raphics, detailed information on antiretroviral treatment, laboratory parameters and clinical events are collected biannually in a standardised format. The study design is described in detail elsewhere [14]. In the study period 2006?013, an average number of 10.400 patients were observed and consecutively monitored at 15 clinical centres in various, predominantly urban areas in Germany. Antiretroviral treatment history, including any interruptions in treatment, is documented in detail in the CSH [14,24]. Treatment duration is calculated individually according to the beginning and end dates of each antiretroviral drug treatment. All ART documentation is assessed manually. Quality control algorithms are applied, and in the case of inconsistencies, the centres are requested to submit the revised data to the RKI [14]. The Robert Koch Institute is the German national public health institute, therefore the Federal Commissioner for Data Protection is the responsible entity for studies which are conducted by the Robert Koch Institute. Information on HIV infection collected in ClinSurv corresponds to the data reported to the RKI according to legal requirements implemented by the national Protection against Infection act (IfSG) of 2001. All patient data collected in ClinSurv are generated during routine care. The German Federal Commissioner for Data Protection therefore waived the need for ethical approval for the ClinSurv study. No written PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/27906190 informed consent is required from patients. The overall person-days observed from persons Anlotinib solubility receiving any antiretroviral treatment between 2006 and 2013 in the CSH were analysed and categorised into three groups: medications that contained approved drugs, medications that contained at least one non-approvedThe number of prescribed DDDs of TCMs derived from ART prescription data was used to determine the number of people living with HIV receiving quarterly SHIcovered TCM containing ART in Germany. The proportion of persons covered by SHI was calculated for each federal state based on the number of persons with SHI and the population number of the respective state. To account for patients PubMed ID:https://www.ncbi.nlm.nih.gov/pubmed/28499442 without SHI (including those privately insured, uninsured, or receiving free medical care) whose prescriptions were not covered in the APD, the number of patients was raised in average by a weighted factor of 16.3 [34]. By adding the numbers of persondays of non-TCM ART segments derived from the CSH, we determined the total number of people living with HIV receiving quarterly ART in Germany. In addition, considering the proportion of person-days with treatment interruption seen in the CSH yielded the number of patients in Germany with ART experience. For an overview of the investigated data sources, see Figures 1 and 2. The estimated number of HIV-infected persons with ART experience was smoothed using a negative binomial regression with quadratic time trend in the period of 2006 to 2013. The statistical errors of these numbers were assumed to be independent. The independent variables considered in the negative binomial regression were the time – measured in quarters since the first quarter in year 2006 – and the square of this time. The latter variable allowed us to adjust for a slowing down of the exponentially increasing trend in the recent years.ResultsClinSurv HIV cohort (CSH)The proportion of person-days with TCM-containing regimens reported in the CSH increased continuouslySchmidt et al. BMC Public Health (2015) 15:Page 4.